Entrada Therapeutics, Inc.TRDANASDAQ
Loading
SG&A Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+10.2%
5Y CAGR+50.9%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+10.2%/yr
Annual compound
5Y CAGR
+50.9%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
7.8x
Strong expansion
Streak
6 yr
Consecutive growthStrong
PeriodValueYoY Change
TTM$41.05M+6.7%
2024$38.47M+19.1%
2023$32.29M+5.4%
2022$30.64M+101.6%
2021$15.20M+190.2%
2020$5.24M+45.2%
2019$3.61M-